Enzolytics Inc. Reports No Sales for 2024, Net Loss Narrows to $394,188, EPS Remains at $0.00
Enzolytics Inc. reported no sales for 2024, a drop from $84,951 in 2023. The net loss narrowed to $394,188 from $2,688,821 the previous year, with EPS remaining at $0.00. Total current assets decreased to $200 million from $360 million, mainly due to reduced investment in SAGA shares. Financial statements were prepared by Camelot Financial, including a balance sheet and income statement.
Enzolytics Inc. has released its financial results for the year ended December 31, 2024. The company reported no sales for the year, a significant decrease from the $84,951 recorded in the previous year. The net loss for 2024 was $394,188, showing an improvement from the net loss of $2,688,821 in 2023. There was no earnings per share (EPS) reported due to the negative financial outcome. The balance sheet shows total current assets of $200 million as of December 31, 2024, compared to $360 million at the end of the previous year. This decrease is primarily attributed to a reduction in investment in SAGA shares, which fell from $360 million to $200 million over the year. Enzolytics Inc.'s financial statements were prepared by Camelot Financial, a consulting firm engaged by the company. The statements include a balance sheet, a statement of income, a statement of cash flows, and accompanying financial notes.
